podcasts hero

Podcasts About Relapsing Polychondritis (RP)

Explore the growing collection of podcasts talking about all aspects of this often-overlooked disease.

lines

Interview with Dr. David Beck

David Beck, MD, PhD was one of the NYU Langone Health researchers who identified VEXAS syndrome. He talks about their groundbreaking research and what they’re doing now to find a biomarker for RP.

Interview with Dr. Rashmi Kanagal-Shamanna

Rashmi Kanagal-Shamanna, MD is a researcher at MD Anderson Cancer Research Center. She discusses the research she’s doing to help identify the link between bone marrow diseases and RP.

Interview with David Bammert

Dave is the President of the Relapsing Polychondritis Foundation. He talks about our research initiatives, Race for RP partnership, and the Full Throttle podcast.

Relapsing Polychondritis

Dr. Joseph Ahearn, Chair, Autoimmunity Institute, Allegheny Health Network (AHN), and Michael Linn, Vice-Chair, Relapsing Polychondritis Foundation, discuss RP.

Relapsing Polychondritis

Dr. Stacey Clardy, a neurologist, discusses the signs and symptoms of relapsing polychondritis to better help healthcare professionals diagnose the disease.

Relapsing Polychondritis

Dr. Eoin Flanagan, a neurologist, discusses different tests and results that may be useful in helping diagnose relapsing polychondritis.

Relapsing Polychondritis is a Lung Disease: My Story

Dr. Marcela Ferrada, an infectious disease physician at Johns Hopkins and an RP patient, shares her experience living with RP.

Relapsing Polychondritis

Dr. Marcela Ferrada, an infectious disease physician at Johns Hopkins and an RP patient, discusses RP.

Confirming RP

Dr. Marcela Ferrada, an infectious disease physician at Johns Hopkins and an RP patient, discusses her work toward finding a test for RP.

Help Us Fuel the Race for RP Research

In the coming years, we’ll learn more about Relapsing Polychondritis (RP) and related autoimmune diseases. But we can’t do it without the support of generous individuals and organizations willing to fuel research that will drive breakthroughs. Join us in our race for a cure.